Affiliation:
1. Department of Breast and Medical Oncology National Center for Global Health and Medicine Tokyo Japan
2. Course of Advanced and Specialized Medicine Juntendo University Graduate School of Medicine Tokyo Japan
3. AIDS Clinical Center National Center for Global Health and Medicine Tokyo Japan
4. Division of Host Defense Mechanism Tokai University School of Medicine Kanagawa Japan
5. National Hospital Organization Higashisaitama Hospital Saitama Japan
Abstract
AbstractBackgroundAntiretroviral therapy has reduced the incidence and mortality of AIDS‐defining malignancies (ADM); however, non–AIDS‐defining malignancies (NADM) are a major cause of death among people living with HIV (PLWH) today. Though current guidelines suggest that PLWH should receive the same treatment as the general population, there are limited studies focused on how HIV status affects the prognosis of cancers. The present study aimed to investigate the characteristics and prognosis of malignant diseases among PLWH in Japan.MethodsPatients with HIV diagnosed with malignant diseases at our institution between 2011 and 2021 were retrospectively reviewed.ResultsThere were 205 patients who were diagnosed with malignancies. Of these, 87 (42.4%) were diagnosed with ADM and 118 (57.6%) were diagnosed with NADM. Among 69 patients who received chemotherapy for ADM, 24 (34.8%) developed AIDS‐defining opportunistic infections during treatment. In contrast, only one (1.8%) of the 56 patients administered chemotherapy for NADM developed AIDS‐defining opportunistic infections. Complications of opportunistic infections at diagnosis of malignancies, low CD4+ T‐cell count, positive HIV RNA, and nonadministration of antiretroviral therapy were associated with 5‐year overall survival among patients with malignant lymphomas. However, the variables associated with HIV did not affect NADM prognosis.ConclusionsIn this analysis, HIV status had a small impact on the prognosis of malignant diseases in PLWH. Few patients with NADM developed AIDS‐defining opportunistic infections after receiving chemotherapy.
Funder
Ministry of Health, Labour and Welfare
Japan Agency for Medical Research and Development